NanoViricides, Inc. · AMEX:NNVC
NanoViricides — LD Micro Conference (February 2020)
30 slides from NanoViricides's conference presentation, February 2020
Slide 1: 7898:;<1<.<=->%<?%9%1-@<?A-1-=%A19=-/91B%:C%!98:*<1<.<=-?3%D8.E% F%GHH%1<@IA?%1-?-1;-=%J%!98:*<1<.<=-?3%D8.E%
!"#$%&'()%&')'#*+,),-.-"&*(-/$)&%)#/$+0.+'#"),'123 !"#$%&'()%!!*+ ,-.-/0-1%23%4562 !"#$%$&'$()*"+,&-.,&-/0& 123$4&!5$6"738$&94436$+ 7898:;<1<.<=->%<?%9%1-@<?A-1-=%A19=-/91B%:C%!98:*<1<.<=-?3%D8.E% F%GHH%1<@IA?%1-?-1;-=%J%!98:*<1<.<=-?3%D8.E%
Slide 2: Disclosure and Forward-Looking Statements
,<?.H:?L1-J%^:1P91=J`::B<8@%#A9A-/-8A? !98:*<1<.<=-?3%D8.E%<?%9%KL0H<.HM%A19=-=%.:/K98M%N?A:.B%?M/0:H)%!!*+3%!"#$%&'(OE%%(I<?%<?%8:A%98%:CC-1<8@%/-/:198=L/%98=%?I:LH=%8:A%0-% .:8?A1L-=%9?%?L.IE%DA%<?%K1:;<=-=%9?%9%8:8J.:8C<=-8A<9H%=:.L/-8A%C:1%<8C:1/9A<:89H%KL1K:?-?%:8HME%% ! !98:*<1<.<=-?3%D8.ENPPP
Slide 3: A nanoviricide in action: at-a-glance
G%898:;<1<.<=-R%<8%9.A<:8%9AJ9J@H98.- %%%=77>62 !%6>?@"A>7$ %%%%.$@7+*( #1 A nanoviricide binds to a virus particle. #2 Bound nanoviricide continuing #3 Acompletely virus particle being encapsulated encapsulation of by a nanoviricide prior to virus particle complete destruction of the envelope resul
Slide 4: Investment Highlights
D8;-?A/-8A%U<@IH<@IA? B$8$+>#3%#&?>7$%7$C&D3*)3)$736&7$62%*A*#(&7*&+>?3CA(&6+$>7$& ?*E$+4"A&%$E&>%73F83+>A&C+"#@&& .3+$67A(&>77>6G&83+"@&?>+736A$@&3%&63+6"A>73*%,&3%C$?$%C$%7&*4&2*@7& H+*>CF@?$67+")&>#$%7@&72>7&>+$&$5?$67$C&7*&6*%73%"$&7*&D$&$44$6738$&3%&@?37$& *4&62>%#$@&3%&83+"@&#$%*)$&I)"7>73*%@,
Slide 5: Financial Overview
^<898.<9H%a;-1;<-P ! _">+7$+A(&*?$+>73%#&$5?$%@$@`&MSJVU&)3AA3*%&I4+*)&+$6$%7&SO_K& ! ! ~M;;&)3AA3*%&3%&6>@2&>%C&$a"38>A$%7@&>@&*4&'$?7&<O,&;OS< ! =8#J&7+>C3%#&8*A")$`&L;OO,OOO&@2>+$@&?$+&C>( ! ! ->+G$7&6>?37>A3Q>73*%`&~M;UO&)3AA3*%& ! '2>+$@&*"7@7>%C3%#`&~UO&)3AA3*% :U
Slide 6: Foundation for Breakthrough Technology
^:L8=9A<:8%C:1%b1-9BAI1:L@I%(-.I8:H:@M =AA&%>%*83+363C$@&6*%@3@7&*4&;&"%3a"$&4$>7"+$@ ! T>%*)36$AA$b)>C$&*4&D3*C$#+>C>DA$&?*A()$+@ B3#>%Cb@)>AA&)*A$6"A>+&c)3)36d&*4&+$6$?7*+&*%&7>+#$7&6$AA T>%*)36$AA$`&D>@$&"@$C&3%&>AA&%>%*83+363C$@e&& ! B3#>%C`&83+"@F@?$63436&@)>AA&)*A$6"A$&72>7&c)3)36@d&72$&+$6$?7
Slide 7: Technology Platform (continued)
%%%%(-.I8:H:@M%eH9AC:1/%N.:8A<8L-=O ! =&%>%*83+363C$&3@&$5?$67$C&7*&D$&$44$6738$&>#>3%@7&72$&83+"@&3%&@?37$&*4& )"7>73*%@&>%C&*72$+&62>%#$@&3%&72$&83+"@&D$6>"@$&72$&+$6$?7*+&@37$&72>7& 72$&83+"@&D3%C@&7*&C*$@&%*7&62>%#$ (I-%/:?A%</K:1A98A%K1:0H-/%C:1%98A<;<19H?%J%;9..<8-?3%98A<0:=<-?3%?/9HH%.I-/<.9H
Slide 8: Historical Precedents
U<?A:1<.9H%e1-.-=-8A? !"#$%&'($)*+,-*.#*)/"0-()-1+"#")'($)-*).-'+"*'2")'-$3- ()3"/'($&0-.(0"*0"0-$#"+-'4"-1*0'-566-,"*+0! !CE>+C&h$%%$+&>%C&@)>AA?*5&8>663%>73*%&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&Si72&1$%7"+(& ! h*@$?2&B3@7$+&>%C&72$&6*%6$?7&*4&>%73@$?@3@&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&SW72&1$%7"+(& ! =
Slide 9: An Influenza Virus
An Influenza Virus Influenza Virus ey Anatomy on —Neuraminidase Lipid P f (Sialidase) Envelope——> 4 Figure 1 ‘ . ~~ ; Capsid we Hemagglutinin &
Slide 10: Virus Infects Cell After Attaching to Receptor Proteins on Surface of Target Cell
*<1L?%D8C-.A?%+-HH%GCA-1%GAA9.I<8@%A:%Y-.-KA:1%e1:A-<8?%:8% #L1C9.-%:C%(91@-A%+-HH T*+)>A&>77>62)$%7&*4&83+"@&7*&2*@7&I7>+#$7K&6$AA :SO
Slide 11: A nanoviricide in action: at-a-glance
G%898:;<1<.<=-R%<8%9.A<:8%9AJ9J@H98.- %%%=77>62 !%6>?@"A>7$ %%%%.$@7+*( #1 A nanoviricide binds to a virus particle. #2 Bound nanoviricide continuing #3 Acompletely virus particle being encapsulated encapsulation of by a nanoviricide prior to virus particle complete destruction of the envelope resul
Slide 12: Nanoviricide mimicking target cell of virus
898:;<1<.<=-%/</<.B<8@%A91@-A%.-HH%:C%;<1L? NANOVIRICIDE ATTACHMENT PROTEINS ON VIRUS SURFACE RECEPTOR PROTEINS TARGET CELL Alveolus :S;
Slide 13: Ligand on nanoviricide mimics receptor on surface of target cell
`<@98=%:8%898:;<1<.<=-%/</<.?%1-.-KA:1%:8%?L1C9.-%:C%A91@-A%.-HH :S<
Slide 14: Virus attaches to mimic on surface of nanoviricide
*<1L?%9AA9.I-?%A:%7/</<.>%:8%?L1C9.-%:C%898:;<1<.<=- =&%>%*83+363C$j@&A3#>%C@&>77>62&7*&72$&83+"@j&>77>62)$%7&?+*7$3%@&3%& 72$&@>)$&)>%%$+&>@&>%(&83+"@&>77>62$@&7*&37@&7>+#$7&6$AA :SN
Slide 15: Nanoviricide pliers the virus
898:;<1<.<=-%?H</-?%AI-%;<1L?f :SU
Slide 16: And Ultimately Destroys the Virus
f98=%_HA</9A-HM%,-?A1:M?%AI-%*<1L? :Sg
Slide 17: Nanoviricide effect on a Cytomegalovirus
898:;<1<.<=-%-CC-.A%:8%9%+MA:/-@9H:*<1L?%N+&*O% 1*%7+*A f+$>7$C (I<?%<?%9%.MA:/-@9H<.%;<1L?%0-<8@%=-?A1:M-=%0M%9%898:;<1<.<=-E% (I-%-8;-H:K-%:C%AI-%;<1L?%I9?%0--8%01-9.I-=%98=%AI-%.9K?<=?% .:8A9<8<8@%AI-%@-8-A<.%/9A-1<9H%91-%?--8%?K<HH<8@%:LAE% G%P-9BHM%-CC-.A<;-%H<@98=%P9?%-/KH:M-=%A:%.9KAL1-%AI<?%
Slide 18: Oral FluCide Flu Drug Forms
4%^HL+<=-h%,:?9@-%^:1/? *+>A&]A"13C$ *+>A&]A"13C$ *+>A&]A"13C$ a19H%L8<AJ=:?-%AP<?AJA:K%9?-KA<.%K9.B9@- i2553555%I:?K<A9H<S-=%K9A<-8A?%P<AI% 25Jc5&%D8CHL-8S9%.9?-?%K-1%M-91%<8%AI-%_#%988L9HHM% <8CHL-8S9%<8%AI-%_#%9H:8-%-;-1M%M-91 b<HH<:8?%:C%.9?-?%P:1H=JP<=-%<8%9%K98=-/<. :Si
Slide 19: FluCide Preclinical Results - Survival
^HL+<=-h%e1-.H<8<.9H%Y-?LHA?%j%#L1;<;9H 0*"+@&*4&@"+838>A&>47$+&A$72>A&3%4A"$%Q>&3%[$673*% :SW
Slide 20: FluCide Preclinical Results - Viral Load
^HL+<=-h%e1-.H<8<.9H%Y-?LHA?%j%*<19H%`:9= LS,OOOF4*AC&B"%#&Y3+>A&B*>C&k$C"673*%&3%&PY&]A"13C$^&f+$>7$C&=%3)>A@& l;F4*AC&+$C"673*%&E372&9@$A7>)383+&3%&723@&@7"C( NJU&.>(@&ISOi2K&/*@7FP%4$673*% :;O
Slide 21: Product Pipeline
e1:=L.A%e<K-H<8- In Vitro Efficacy- IND-Enabling Human Disease & Indication Drug Candidate Development Animals Studies Clinical Trials Primary Programs Hospitalized Patients; Injectable Pandemic, Epidemic, All Influenzas FluCide™ Seasonal, Bird Flu Out-Patients; Pandemic, Epidemic, Oral FluCide™ All
Slide 22: $50 Billion Global Market
>k]5%b<HH<:8%lH:09H%&91B-A $Billions, Disease / Virus estimate HIV/AIDS $ 25 B Influenzas $ 10 B Eye Drops Antiviral $ 1-5 B Herpes “Cold Sores” Skin Cream & Gel $ 2-5 B Hepatitis C $ 5-10 B Dengue, Rabies, other NTD’s (combined) $ 1-5 B Ebola/Marburg/VHF (combined) $1B :;;
Slide 23: Global First-in-Class Intellectual Property
lH:09H%7^<1?AJ<8J+H9??>%D8A-HH-.AL9H%e1:K-1AM &]3$ACFC$43%3%#,&?3*%$$+3%#,&?A>74*+)&7$62%*A*#(&$%>DA$@&%>%*83+363C$@&C+"#@&& ! &-*+$&72>%&@$8$%7(F438$&?>7$%7@&3@@"$C&7*&C>7$&3%&;U&6*"%7+3$@,&3%6A"C3%#&72$& mJ'J,&="@7+>A3>,&h>?>%,&123%>,&1>%>C>,&>%C&>AA&*4&=4+36> &LSOO&6*"%7+3$@&$5?$67$C&7*&>??+*8$&?
Slide 24: Regulatory Recognition
Y-@LH9A:1M%Y-.:@8<A<:8 f2$&mJ'J&].=&>%C&72$&!"+*?$>%&-$C363%$@&=#$%6(& +$6$%7A(&#+>%7$C&c*+?2>%&C+"#d&C$@3#%>73*%&7*& .$%#"$13C$^,&72$&T>%*Y3+363C$@&C+"#&4*+&.$%#"$&]$8$+& >%C&.$%#"$&0$)*++2>#36&]$8$+& ! T>%*Y3+363C$@&E>@&#+>%7$C&>%&$>+A(&?+$FPT.&)$$73%#&D(& 72$&m'&].=,&2$AC&3%&->+62&;OS;,&4*+&]A"13
Slide 25: Partners and Collaborators
e91A8-1?%98=%+:HH90:19A:1? H3*A*#36@&1*%@"A73%#&\+*"?&IH1\,& +$#"A>7*+(&6*%@"A7>%7@K& m1&H$+G$A$(,&'62**A&*4&/"DA36&0$>A72& H='3&I\B/&@>4$7(X7*536*A*#(&@7"C3$@K& ! ! T*+72$>@7&923*&m%38$+@37(&1*AA$#$&*4&-$C363%$& ]$3%@7$3%&P%@737"7$&*4&-$C36>A&k$@$>+62& ! ! B'm&'62**A&*4&Y$7$+3%>+(&-$C363%$& '*"72$+
Slide 26: Manufacturing Capability
&98LC9.AL1<8@%+9K90<H<AM In the process of negotiating a lease agreement for a fully operational 18,000 square feet R&D laboratory with cGMP manufacturing capabilities Construction expected to be complete by Q1 2014 We expect that the cGMP plant will be capable of manufacturing any of the NanoVirici
Slide 27: Goals and Milestones
l:9H?%98=%&<H-?A:8-? ;OS<&-3A$@7*%$@& ✓ 1*)?A$7$C&%*%F\B/&7*536*A*#(&@7"C3$@&4*+&]A"13C$^,& ;OSN&\*>A@& P%3p>7$&]A"13C$^&\B/&@>4$7(X7*536*A*#(&@7"C3$@& E372&$56$AA$%7&@>4$7(&C$)*%@7+>73*%& 7*E>+C@&PT.&& ✓ /+*C"673*%&'6>A$F"?&>%C&62>+>67$+3Q>73*%&@7"C3$@&4*+& ]A"13C$^&?+*#+$@@3%#&@>73@4>67*+3A(& 1*%C
Slide 28: Risk Factors - Technology
Y<?B%^9.A:1?J(-.I8:H:@M o$@J&n2$%$8$+&E$&$%#>#$&3%7*&43+@7&>%3)>A&$4436>6(&@7"C(,&E$&7$@7&@>4$7(&*4&72>7&C+"#&6>%C3C>7$J& '>4$7(&3@&D"3A7&3%7*&72$&6*)?*@373*%&>%C&C$@3#%&*4&72$&%>%*)36$AA$&37@$A4J&H$@3C$@,&E$&C$@3#%&72$& @0-('-B*3"C >%7383+>A&A3#>%C@,&>@&E$AA&>@&%>%*83+363C$&6*%@7+"673*%&62$)3@7+3$@
Slide 29: Risk Factors - Corporate
Y<?B%^9.A:1?%J%+:1K:19A- u&T>%*Y3+363C$@&2>@&6>J&M;;-&3%&6>@2&v&$a"38>A$%7@&I'$?7&<OK,&>%C&@?$%C@&>D*"7&Mg-&6>@2&?$+&($>+J&& u&n$&D$A3$8$&E$&2>8$&@"44363$%7&6>@2&+$@$+8$@&7*&7>G$&]A"13C$&>%C&?*@@3DA(&.$%#"$13C$&72+*"#2&3%373>A& I*1('*%-!(0= 2")>%&6A3%36>A&7+3>A@J&& u&9"+&C+"#&C$8$A*?)$%7&6*@7@&2>8$&
Slide 30: In Summary
D8%#L//91M B$8$+>#3%#&?>7$%7$C&7$62%*A*#(&7*&+>?3CA(&6+$>7$&?*E$+4"A&%$E&C+"#@&72>7& 2>8$&72$&>D3A37(&7*&C$@7+*(&)*@7&>AA&83+"@$@&3%&>%C&*%&72$&D*C(J& ! /+$6A3%36>A&@7>#$&?+*C"67@&>CC+$@@3%#&8$+(&A>+#$&)>+G$7@&ILMNOHK& P%4A"$%Q>&I@$>@*%>A,&0STS,&0VTW,&$76JK&F&P%[$67>DA$&C+"#& P%4A"$%Q>&I@$>@*%>A,&0S